• Perineuronal Net Degradation Impairs Social Memory in AD Mod

  2026-04-25

  This study demonstrates that loss of perineuronal nets (PNNs) in the hippocampal CA2 region underlies social cognition deficits in Alzheimer’s disease (AD) mouse models. By linking PNN disruption to upregulated matrix metalloproteinase (MMP) activity and showing that MMP inhibition preserves social memory, the research establishes extracellular matrix integrity as a critical factor in neurodegeneration.

• Deferasirox: Oral Iron Chelator Workflows for Cancer Researc

  2026-04-24

  Deferasirox, a clinically validated oral iron chelator, is revolutionizing both iron overload management and experimental oncology by targeting iron metabolism and ferroptosis resistance. This article delivers actionable protocols, troubleshooting strategies, and translational insights to maximize reproducibility and impact in cancer and hematology research.

• HotStart 2X Green qPCR Master Mix: Precision for Gene Expres

  2026-04-24

  Unlock exceptional specificity and reproducibility in real-time PCR gene expression analysis with HotStart™ 2X Green qPCR Master Mix. Explore advanced, evidence-backed workflows, application-driven troubleshooting, and practical insights that translate the latest immune evasion research into actionable assay design advantages.

• Harnessing PPM-18 for NF-κB Pathway Inhibition in Sepsis Res

  2026-04-23

  PPM-18 (N-(1,4-dihydro-1,4-dioxo-2-naphthalenyl)-benzamide) stands out as a next-generation iNOS expression inhibitor, enabling precise control over NF-κB signaling in inflammation and sepsis models. This article delivers actionable workflows, troubleshooting insights, and translational tips to maximize reproducibility and scientific rigor with APExBIO's trusted compound.

• COX-2 Pathway’s Role in Muscle Ischemia and Revascularizatio

  2026-04-23

  This study investigates how the cyclooxygenase-2 (COX-2) pathway modulates tissue ischemia and revascularization after skeletal muscle injury induced by Bothrops asper venom. Using lumiracoxib, a selective COX-2 inhibitor, the authors reveal that early inhibition of COX-2 aggravates ischemia but enhances late-stage angiogenic signaling and microvascular remodeling, refining our understanding of COX-2’s dual role in muscle regeneration.

• Discovery of 14-3-3 Interactors ATG9A, PTOV1 in Cancer Mecha

  2026-04-22

  This study identifies ATG9A and PTOV1 as novel 14-3-3 binding proteins, uncovering their regulatory roles in autophagy and oncogenic signaling. The findings provide mechanistic insight into basal autophagy and PTOV1 stability, with implications for cancer biology and potential therapeutic targeting.

• Fumagillin: Bridging Angiogenesis and Antiparasitic Frontier

  2026-04-22

  This thought-leadership article explores Fumagillin’s dual role as a methionine aminopeptidase-2 inhibitor in both angiogenesis and antiparasitic research. By dissecting mechanistic insights, experimental validation, protocol parameters, and translational impact, the article provides strategic guidance for researchers navigating cancer and infectious disease models. It integrates evidence from peer-reviewed studies and highlights the competitive landscape, while positioning APExBIO’s Fumagillin as a benchmark reagent for cross-domain translational workflows.

• Gallein and the Translational Power of Gβγ Subunit Inhibitio

  2026-04-21

  This article explores the mechanistic and translational significance of targeting G protein βγ subunit signaling with Gallein, a precision tool for dissecting and modulating GPCR pathways across cancer, immunology, and cardiometabolic research. By integrating the latest evidence from insulin-independent glucose uptake studies, the piece offers actionable guidance and protocol clarity for translational researchers, anchored by APExBIO's expertise and differentiated from standard product narratives.

• IL-34-Driven Macrophage Reprogramming Enables Immune Escape

  2026-04-21

  This study elucidates how p53 inactivation in cancer cells leads to the secretion of interleukin-34 (IL-34), which reprograms tumor-associated macrophages (TAMs) through the IL-34-CD36 axis, promoting tumor immune escape. These insights reveal a critical link between p53 status and the tumor immune microenvironment, offering new therapeutic targets for p53-mutant cancers.

• LMO2–LDB1 Complex Drives AML Progression: Mechanisms and Imp

  2026-04-20

  This article reviews recent findings on how the interaction between LMO2 and LDB1 promotes acute myeloid leukemia (AML) development. The study combines genetic knockdown, mass spectrometry, and transcriptomic analyses to reveal the oncogenic role of the LMO2/LDB1 complex and its impact on leukemia cell survival and proliferation.

• HBsAg Manipulates TBK1 to Suppress IFN-I and Trigger Autopha

  2026-04-20

  This study uncovers how hepatitis B surface antigen (HBsAg) directly manipulates TANK-binding kinase 1 (TBK1), suppressing type I interferon production and initiating early autophagy in hepatocytes. These mechanistic insights advance understanding of HBV immune evasion and suggest new targets for antiviral and autophagy-modulating strategies.

• L-Ornithine in CNS–Liver Axis Research: Mechanistic Frontier

  2026-04-19

  This article delivers a mechanistic deep-dive into L-Ornithine’s dual role in hepatic ammonia detoxification and CNS toxicity, guided by the latest evidence on liver–brain metabolic crosstalk. Bridging foundational biochemistry with translational guidance, we provide researchers with actionable protocol parameters, critical appraisal of current workflows, and strategic foresight into the evolving landscape of metabolic and neurological research using APExBIO’s high-purity L-Ornithine.

• Phenytoin and AEDs: Inhibition of Human Serum Paraoxonase-1

  2026-04-18

  This study investigates how common antiepileptic drugs, including phenytoin (5,5-diphenylimidazolidine-2,4-dione), inhibit human serum paraoxonase-1 (hPON1) in vitro. The findings reveal noncompetitive inhibition mechanisms and provide quantitative inhibition parameters, which are crucial for understanding drug interactions with key enzymatic antioxidants.

• SU6656 Src Tyrosine Kinases Inhibitor: Redefining Megakaryoc

  2026-04-17

  Explore how SU6656, a potent Src tyrosine kinases inhibitor, is reshaping protocols for megakaryocyte polyploidization and enhancing radiotherapy outcomes. This article provides a novel, evidence-driven perspective on integrating SU6656 into advanced platelet production and cancer research workflows.

• 3D versus 2D Models Reveal ATR Inhibitor Radiosensitization

  2026-04-16

  This study systematically compares targeted radiosensitizers, including ATR inhibitors, across 2D and 3D cancer cell cultures. The findings highlight the importance of physiologically relevant models for robust preclinical screening and prioritization of radiosensitizing agents.

16180 records 1/1079 page Next 12345 下5页 Last page